Literature DB >> 17702729

Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population.

Arash Rashidi1, Arash Ghanbarian, Fereidoun Azizi.   

Abstract

BACKGROUND AND OBJECTIVES: Recently, metabolic syndrome (MS) was suggested to be an independent risk factor for chronic kidney disease (CKD). This study explored the relationship between MS and risk for development of CKD that is independent of diabetes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study population consisted of 4607 adult (age >18 yr) individuals who did not have diabetes or CKD at baseline and were successfully followed for 3 yr in the Tehran Lipid and Glucose Study, a prospective, population-based study of risk factors for atherosclerosis and diabetes. Individuals with and without MS at baseline were compared regarding development of new CKD.
RESULTS: A total of 1010 (21.9%) individuals met criteria for MS at baseline. During the follow-up, 38 (3.4%) individuals in MS group and 73 individuals (2.0%) of 3590 people in non-MS group developed CKD (OR = 1.88, 95% CI; 1.26-2.8). After exclusion of individuals with hypertension at baseline (n = 798), 406 people (10.7%) were defined as having MS. After follow-up, 62 (1.82%) people in the MS group and eight (1.98%) people in non-MS group developed CKD (OR = 0.925, 95% CI; 0.446-1.917; P = 0.844).
CONCLUSIONS: The results of this study suggest that MS is a cluster of multiple risk factors, and, as a cluster, it is a significant risk for CKD. The risk of MS for developing CKD is highly affected by the presence of diabetes and hypertension, and it seems that clustering of individual risk factors is more plausibly associated with risk for developing CKD than a unique biologic phenomenon.

Entities:  

Mesh:

Year:  2007        PMID: 17702729     DOI: 10.2215/CJN.01020207

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  21 in total

Review 1.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

2.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

Review 3.  Metabolic syndrome and kidney disease: a systematic review and meta-analysis.

Authors:  George Thomas; Ashwini R Sehgal; Sangeeta R Kashyap; Titte R Srinivas; John P Kirwan; Sankar D Navaneethan
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-18       Impact factor: 8.237

Review 4.  Metabolic syndrome and chronic kidney disease: Current status and future directions.

Authors:  G V Ramesh Prasad
Journal:  World J Nephrol       Date:  2014-11-06

5.  Identification of modifiable chronic kidney disease risk factors by gender in an African-American metabolic syndrome cohort.

Authors:  Loretta Jackson Brown; Patricia C Clark; Karen A Armstrong; Zhao Liping; Sandra B Dunbar
Journal:  Nephrol Nurs J       Date:  2010 Mar-Apr       Impact factor: 0.959

Review 6.  Impact of treating the metabolic syndrome on chronic kidney disease.

Authors:  Varun Agrawal; Aashish Shah; Casey Rice; Barry A Franklin; Peter A McCullough
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

Review 7.  New aspects of the relationship among hypertension, obesity, and the kidneys.

Authors:  Anja Sachse; Gunter Wolf
Journal:  Curr Hypertens Rep       Date:  2008-04       Impact factor: 5.369

8.  Metabolic syndrome and renal injury.

Authors:  Yi-Jing Sheen; Wayne Huey-Herng Sheu
Journal:  Cardiol Res Pract       Date:  2011-03-13       Impact factor: 1.866

9.  Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad.

Authors:  Mário Raimundo; José António Lopes
Journal:  Cardiol Res Pract       Date:  2011-02-20       Impact factor: 1.866

10.  The determinants of complication trajectories in American Indians with type 2 diabetes.

Authors:  Evan L Reynolds; Gulcin Akinci; Mousumi Banerjee; Helen C Looker; Adam Patterson; Robert G Nelson; Eva L Feldman; Brian C Callaghan
Journal:  JCI Insight       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.